Pay in 4 interest-free payments of $6.99 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
New England Journal of Medicine, 363(2), 109-122
The result is a cascade of changes in how digestion feels: Gastric emptying slows significantly
Concurrently, advanced molecular therapeutics are emerging, including mitophagy inducers (e.g., urolithin A, nicotinamide riboside) to restore mitochondrial quality control (187, 188), gut microbiome engineering to reduce systemic inflammation (189), and innovative RNA therapeutics and gene circuits (e.g., olezarsen, the CHARM system) for long-term management of dyslipidemia (182, 183)
95% CI: 0.53 to 0.73), respectively
US$ 21.35
US$ 26.02
US$ 23.10
US$ 20.84
US$ 24.77
